Clinic
Julia Barriga M.D., P.A.
Julia Barriga M.D., P.A. was paid $6.59M by Medicaid between Jan 2019 and Dec 2024, across 82 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 25% of everything it billed.
33Billing provider infoJULIA BARRIGA M.D., P.A.
TAMPA, FL 33617
TAMPA, FL 33617
33aNPI1942367644assigned 01/02/2007
33bProvider typePrimary Care Clinic/Center
28Total paid$6.59M
24GClaims297,963
24DCodes billed82
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Florida
Rank by total paid#5 of 215
Median peer was paid$25K
This provider vs. median265×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 39,056 | $836K | |
| 2020 | 51,219 | $941K | |
| 2021 | 48,905 | $1.12M | |
| 2022 | 56,365 | $1.58M | |
| 2023 | 56,969 | $1.35M | |
| 2024incomplete | 45,449 | $757K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 25% | 16,686 | 15,164 | $1.65M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 14,318 | 13,277 | $949K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 10% | 6,346 | 6,099 | $667K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9.9% | 6,142 | 5,910 | $650K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.8% | 4,100 | 3,960 | $445K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 6.1% | 25,605 | 16,183 | $401K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.4% | 3,705 | 3,479 | $357K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.5% | 2,898 | 2,708 | $298K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 4,642 | 4,363 | $176K |
| 99188 | 2.3% | 14,748 | 14,145 | $154K | |
| 92552 | 2.2% | 11,278 | 10,881 | $145K | |
| 97803 | 2.2% | 12,040 | 11,632 | $144K |
70 more codes
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.3% | 14,598 | $86K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 6,323 | $81K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,471 | $43K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 9,177 | $35K |
| 99381 | <1% | 483 | $35K | |
| 96160 | <1% | 27,860 | $29K | |
| 94150 | <1% | 5,147 | $28K | |
| 85018 | <1% | 22,931 | $24K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,809 | $24K |
| 99383 | <1% | 254 | $22K | |
| 99051 | <1% | 3,728 | $19K | |
| 99382 | <1% | 166 | $13K | |
| 99496 | <1% | 334 | $11K | |
| 92567 | <1% | 2,992 | $11K | |
| 87807 | <1% | 1,924 | $8K | |
| 90677 | <1% | 195 | $8K | |
| 96127 | <1% | 5,027 | $8K | |
| 99384 | <1% | 72 | $7K | |
| 83655 | <1% | 1,815 | $6K | |
| 0072A | <1% | 142 | $6K | |
| 99201 | <1% | 58 | $5K | |
| 0002A | <1% | 138 | $5K | |
| 0001A | <1% | 187 | $5K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 60 | $5K |
| 0071A | <1% | 152 | $4K | |
| 90671 | <1% | 19 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,707 | $3K |
| 90670 | <1% | 2,487 | $2K | |
| 90716 | <1% | 1,489 | $2K | |
| 94760 | <1% | 4,253 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 437 | $2K |
| 90619 | <1% | 34 | $1K | |
| 90686 | <1% | 4,011 | $1K | |
| 96161 | <1% | 1,921 | $976.72 | |
| 90633 | <1% | 1,663 | $721.92 | |
| 90697 | <1% | 12 | $628.20 | |
| 99173 | <1% | 13,505 | $562.72 | |
| 90674 | <1% | 186 | $376.43 | |
| 90700 | <1% | 3,634 | $338.15 | |
| 81002 | <1% | 451 | $302.40 | |
| 90707 | <1% | 1,405 | $287.55 | |
| 94664 | <1% | 160 | $266.53 | |
| 90648 | <1% | 2,252 | $228.62 | |
| 90651 | <1% | 2,368 | $194.96 | |
| 90713 | <1% | 2,842 | $181.70 | |
| 90687 | <1% | 93 | $179.23 | |
| 91307 | <1% | 315 | $178.98 | |
| 90744 | <1% | 1,161 | $142.45 | |
| S8110 | Peak expiratory flow rate (physician services) | <1% | 28 | $67.14 |
| 90620 | <1% | 745 | $60.00 | |
| 91300 | <1% | 304 | $40.00 | |
| 90688 | <1% | 381 | $36.04 | |
| 90685 | <1% | 74 | $30.00 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 123 | $24.44 |
| 90656 | <1% | 112 | $23.60 | |
| 81003 | <1% | 15 | $10.10 | |
| 99499 | <1% | 1,375 | $1.04 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $0.90 |
| 90715 | 0% | 355 | $0.00 | |
| 90681 | 0% | 816 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 1,913 | $0.00 |
| 90734 | 0% | 1,281 | $0.00 | |
| 90461 | 0% | 142 | $0.00 | |
| 99072 | 0% | 1,249 | $0.00 | |
| 80061 | Lipid panel | 0% | 17 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 14 | $0.00 |
| 3008F | 0% | 8,286 | $0.00 | |
| 1111F | 0% | 242 | $0.00 | |
| 36416 | 0% | 481 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRANDE, GIULIANA (PRACTICE MANAGER)